Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 3,504 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult-Onset Diabetes Mellitus Clear all
Recruiting Phase 3 Interventional

Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

NCT07428746
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide
Drug
Lead sponsor
Emory University
Other
Eligibility
65 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

NCT02288273
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Bydureon, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
29
States / cities
Anaheim, California • Chino, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

NCT06340854
View directory record Official record
Conditions
Diabetes, Type 2
Interventions
Insulin icodec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
27
States / cities
Fresno, California • Hawthorne, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes

NCT02960659
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Liraglutide, Metformin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Phase 1 Interventional

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)

NCT07242469
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
MK-1403 + additive coformulation, Placebo + additive coformulation
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Anaheim, California • Chula Vista, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

NCT04450394
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LY3209590, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
31
States / cities
Sheffield, Alabama • Huntington Park, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 16, 2026, 3:24 AM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
204
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

NCT02058160
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
108
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Phase 1Phase 2 Interventional

Ginkgo Biloba Extract and the Insulin Resistance Syndrome

NCT00032474
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ginkgo biloba extract
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
20 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

NCT01007097
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
TAK-875, Glimepiride, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
64
States / cities
Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Not applicable Interventional

Shared Decision Making With Pharmaceutical Care

NCT02373059
View directory record Official record
Conditions
Diabetes
Interventions
Diabetes Issue Cards Decision Aids, Usual Pharmaceutical Care
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Kasson, Minnesota
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 16, 2026, 3:24 AM EDT
Terminated Not applicable Interventional

Biweekly Interval Intermittent Fasting for Type 2 Diabetes, a Safety Study

NCT03938441
View directory record Official record
Conditions
Diabetes Type 2, Pre-diabetes
Interventions
Intermittent Fasting
Other
Lead sponsor
gino gaddini
Federal
Eligibility
18 Years to 69 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Not applicable Interventional Results available

Pilot Project of Health Promotion for People With Diabetes

NCT00970294
View directory record Official record
Conditions
Diabetes
Interventions
Health Promotion Program
Behavioral
Lead sponsor
Patricia Kluding, PhD
Other
Eligibility
40 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 16, 2026, 3:24 AM EDT
Recruiting Not applicable Interventional

Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes

NCT06836479
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
Interventions
NOURISH Diet, Self-Selected Diet (Control)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 16, 2026, 3:24 AM EDT
Active, not recruiting Phase 4 Interventional

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

NCT07325435
View directory record Official record
Conditions
Type 2 Diabetes (T2DM)
Interventions
SGLT-2 inhibitor, GLP1-RA
Drug
Lead sponsor
MaryAnn Banerji
Other
Eligibility
24 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 16, 2026, 3:24 AM EDT
Terminated Not applicable Interventional

SeaCare's Care Coordination for Diabetes Management in a Primary Care Office

NCT00965510
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
care coordination
Behavioral
Lead sponsor
SeaCare Health Services
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Exeter, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 30, 2011 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients

NCT02008942
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PL2200 Aspirin Capsules, Enteric-coated aspirin caplets
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
21 Years to 79 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
3
States / cities
Miami, Florida • Lenexa, Kansas • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Phase 2 Interventional Results available

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

NCT03922750
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine U100
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
13
States / cities
Walnut Creek, California • Roswell, Georgia • Idaho Falls, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

NCT00754988
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Metformin, Placebo (matching sitagliptin), Placebo (matching taspoglutide), Sitagliptin, Taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
64
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tallassee, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Not applicable Interventional

Continuous Glucose Monitoring, Contingency Management, and Motivational Interviewing for Patients With Type 2 Diabetes in Kansas City

NCT06374186
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Behavioral Intervention with financial rewards and coaching, Control
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 16, 2026, 3:24 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion

NCT05264727
View directory record Official record
Conditions
Healthy, Type 2 Diabetes, Obesity
Interventions
Dextrose, Clinisol 15%
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 16, 2026, 3:24 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06660173
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Maridebart Cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Anaheim, California • Canoga Park, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation

NCT01821079
View directory record Official record
Conditions
Healthy
Interventions
PF-05175157
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 16, 2026, 3:24 AM EDT
Completed Phase 1 Interventional

Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe

NCT00127296
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
Interventions
FlexPen®, vial and syringe
Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
40 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 16, 2026, 3:24 AM EDT